BridgeBio Pharma Inc. (BBIO) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer
BridgeBio Pharma Inc. (BBIO) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (54/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (-14.4% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
BBIO Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING
Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BBIO)
No recent open-market Form 4 cluster sales or emergency dumps flagged on BBIO. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring BBIO)
- ✓Live walkthrough of BBIO's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
BBIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +126.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BBIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BBIO. Explore sector supply chains on /butterfly.
BBIO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDAre BBIO insiders and hedge funds buying or selling?
Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BBIO leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.